Latest News from Origin
New investment – Desktop Genetics
We are delighted to have participated in a seed funding round for Desktop Genetics. The company produces software used in the design and execution of genome editing experiments, a market that is experiencing enormous growth. The company’s core platform, DESKGEN, is used with the world-leading CRISPR/Cas editing technology.
Origin Capital Q2 2015 News
Please click here to read a round up of our latest news.
Co-invest with Origin Capital – update!
We are pleased to announce that we have recently been accepted as an Appointed Representative of Larpent Newton Ltd, which is authorised and regulated by the Financial Conduct Authority (“FCA”). This new status means we are now able to offer third parties the opportunity to co-invest in our transactions.